BackAdial Pharmaceuticals- Warrants (31/07/2023) Overview
Adial Pharmaceuticals Inc - Warrants (31/07/2023)

Adial Pharmaceuticals- Warrants (31/07/2023) Return on Equity

Adial Pharmaceuticals- Warrants (31/07/2023) (ADILW) has a ROE of 150.61%, above the Healthcare sector average of 22.01%.

Get informed when a big investor buys or sells

+ Follow

ROE

150.61%

Return on Equity

150.61%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Adial Pharmaceuticals- Warrants (31/07/2023) (ADILW) FAQ

The latest ROE for ADILW is 150.61%. That is above the Healthcare sector average of 22.01%. Investors often review this figure alongside Adial Pharmaceuticals- Warrants (31/07/2023)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, ADILW currently prints 150.61% for ROE, while the sector average sits near 22.01%. That is roughly 584.3% above the sector mean. Large gaps often invite a closer look at Adial Pharmaceuticals- Warrants (31/07/2023)'s growth, margins, and balance sheet.

Return on Equity shows how effectively Adial Pharmaceuticals- Warrants (31/07/2023) converts resources into returns. At 150.61%, ADILW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ADILW's ROE (150.61%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Adial Pharmaceuticals- Warrants (31/07/2023)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.